A regulatory advisory from law firm Davis Wright Tremaine, published July 23, 2026, examines three key compliance areas: GLP-1 product claims, hidden fee practices, and 'Made in USA' labeling. The piece, part of the firm's Stay ADvised series, provides guidance for companies navigating these…
The advisory covers the area of GLP-1 claims, which typically involve products related to glucagon-like peptide-1 receptor agonists. These substances have gained significant attention in recent years for applications such as weight management and diabetes care. The advisory discusses the regulatory considerations that companies must account for when making claims about such products, though it does not specify particular enforcement actions or new guidance.
Another topic in the advisory is hidden fees, a subject that has drawn increasing attention from regulators and consumer advocates. The piece addresses the compliance challenges businesses face when additional charges are not clearly disclosed upfront. This area touches on advertising practices, pricing transparency, and the potential for regulatory action under existing consumer protection laws.
The third focus of the advisory is the 'Made in USA' labeling standard. Companies that market products with this claim must ensure they meet the applicable regulatory criteria regarding where components are sourced and where manufacturing occurs. The advisory outlines the current framework companies should follow to avoid misleading consumers or running afoul of federal trade regulations.
Davis Wright Tremaine, a national law firm with offices across the United States, publishes the Stay ADvised series to help clients stay informed about advertising, marketing, and regulatory law developments. Each installment typically covers multiple issues that businesses may encounter in their operations. This particular edition, categorized as Regulatory, offers a snapshot of three distinct areas where compliance demands are evolving.
Peptides referenced: Glucagon, GLP-1.
Related reading: FDA panel votes to allow compounding of unapproved peptides in win for RFK Jr., Lilly Plans FDA Filing for Retatrutide After New Phase 3 Data, FDA panel to weigh peptide compounding amid conflict concerns, Peptides Gain Favor on First Day of FDA Compounding Meeting.